Efficiency of Mesenchymal Stem Cells in Treatment of Urinary Incontinence: a Systematic Review on Animal Models

Fazeli, Zahra; Faramarzi, Sepideh; Ahadi, Alireza; Omrani, Mir Davood; Ghaderian, Sayyed Mohammad Hossein

doi:10.2217/rme-2018-0040

Cited by 4 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was not ruled out that the transplantation of mesenchymal MSCs leads to neovascularization and restoration of muscle cells in animal models of incontinence via the paracrine process [ 12 ] or through the exosome production [ 23 , 24 ].…”

Section: Msc Incontinence Correction In Experimental Modelsmentioning

confidence: 99%

See 1 more Smart Citation

Cell Technologies in the Stress Urinary Incontinence Correction

et al. 2022

View full text Add to dashboard Cite

The scientific literature of recent years contains a lot of data about using multipotent stromal cells (MSCs) for urinary incontinence correction. Despite this, the ideal treatment method for urinary incontinence has not yet been created. The cell therapy results in patients and experimental animals with incontinence have shown promising results, but the procedures require further optimization, and more research is needed to focus on the clinical phase. The MSC use appears to be a feasible, safe, and effective method of treatment for patients with urinary incontinence. However, the best mode for application of cell technology is still under study. Most clinical investigations have been performed on only a few patients and during rather short follow-up periods, which, together with an incomplete knowledge of the mechanisms of MSC action, does not make it possible for their widespread implementation. The technical details regarding the MSC application remain to be identified in more rigorous preclinical and clinical trials.

show abstract

Section: Msc Incontinence Correction In Experimental Modelsmentioning

confidence: 99%

“…Various types of MSCs have been investigated for use in the repair of the external sphincter and striated muscle tissue of the urethra. The use of MSCs appears to be a feasible and safe method with promising results for treatment of patients with incontinence [ 4 , 6 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Cell Technologies in the Stress Urinary Incontinence Correction

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Larsson et al found that isolated cloned human urothelial cells can self-renew in vitro and fully differentiate in vivo [14]. In addition, there have been multiple studies investigating the effects of mesenchymal stem cells on neovascularization and the recovery of urinary incontinence [15,16]. In 2019, we successfully localized and isolated female STM stem cells [17].…”

Section: Introductionmentioning

confidence: 99%

Development of Male External Urethral Sphincter and Tissue-Resident Stem/Progenitor Cells in Rats

Zhou

Reed‐Maldonado

Tan

et al. 2020

Stem Cells and Development

View full text Add to dashboard Cite

Stress urinary incontinence (SUI) after prostate surgery is primarily caused by urethral sphincter damage. There are few effective therapeutic approaches for male SUI due to both insufficient study of the structure of the external urethral sphincter (EUS) and incomplete understanding of the resident EUS stem/progenitor cells. The goals of this study were to localize and to determine the distribution of tissue-resident stem/progenitor cells in the male EUS throughout EUS development and to understand the anatomic temporal patterns of the EUS. Newborn Sprague Dawley rats were intraperitoneally injected with the thymidine analogue, 5-ethynyl-2-deoxyuridine (EdU), and the EUS was harvested at five time points (1, 2, 3, 4, and 8 weeks postinjection). The tissue was then processed for EdU staining and immunofluorescence staining for stem cell markers Ki67 and proliferating cell nuclear antigen. We counted the EdU+ label-retaining cells (LRCs) at each time point and colocalized with each stem cell marker, also we isolated and cultured the cells in vitro. The results revealed that the number of EdU+ LRCs in each EUS cross-section decreased over time and that the LRCs were located immediately under the basal membrane of laminin, densely adherent to the muscle fibers. In addition, the thickness of the striated muscle layer developed much faster than the smooth muscle layer during EUS development. By 4 weeks, the structure of the EUS layers was well differentiated. The EUS resident stem/progenitor cells were isolated with MACS Ò MicroBeads system, and myogenesis was confirmed. In this study, we defined both the time-course development of the EUS and the distribution of resident stem/progenitor cells. This information is crucial for forthcoming studies regarding male micturition and for development of novel therapeutic approaches for postoperative male SUI.

show abstract

“…New approaches are being considered to improve the treatment, but its development is still uncertain (eg, 3D bioprinted muscle 16 or tissue engineering 17 ). Mesenchymal stem cells (MSCs) have demonstrated, in experimental models, safety and efficacy against urinary incontinence 18 . But not only MSCs have demonstrated their efficiency in experimental models; in recent years, the proteins secreted by MSCs are generating interesting expectations for the treatment of urinary incontinence 19,20 .…”

Section: Introductionmentioning

confidence: 99%

“…Mesenchymal stem cells (MSCs) have demonstrated, in experimental models, safety and efficacy against urinary incontinence. 18 But not only MSCs have demonstrated their efficiency in experimental models; in recent years, the proteins secreted by MSCs are generating interesting expectations for the treatment of urinary incontinence. 19,20 Numerous safety clinical trials have also been developed to analyze the safety of different MSCs for the treatment of urinary incontinence 21 ; unfortunately, there are many differences between cellular origin, application system, and follow-up.…”

mentioning

confidence: 99%

Two phase I/II clinical trials for the treatment of urinary incontinence with autologous mesenchymal stem cells

García‐Arranz

Alonso-Gregorio

Fontana-Portella

et al. 2020

Stem Cells Translational Medicine

View full text Add to dashboard Cite

We proposed to evaluate the safety and feasibility of adipose-derived mesenchymal stem cells to treat endoscopically urinary incontinence after radical prostatectomy in men or female stress urinary. We designed two prospective, nonrandomized phase I-IIa clinical trials of urinary incontinence involving 9 men (8 treated) and 10 women to test the feasibility and safety of autologous mesenchymal stem cells for this use. Cells were obtained from liposuction containing 150 to 200 g of fat performed on every patient. After 4 to 6 weeks and under sedation, endoscopic intraurethral injection of the cells was performed. On each visit (baseline, 1, 3, 6, and 12 months), clinical parameters were measured, and blood samples, urine culture, and uroflowmetry were performed. Every patient underwent an urethrocystoscopy and urodynamic studies on the first and last visit. Data from pad test, quality-of-life and incontinence questionnaires, and pads used per day were collected at every visit. Statistical analysis is made by Wilcoxon signed-rank test. No adverse effects have been collected. Three men (37.5%) and five women (50%) showed an objective improvement of >50% (P < .05) and a subjective improvement of 70% to 80% from baseline. In conclusion, intraurethral application of stem cells derived from adipose tissue is a safe and feasible procedure to treat urinary incontinence after radical prostatectomy or in female stress urinary incontinence. A statistically significant difference was obtained for pad-test improvement in 3/8 men and 5/10 women. Our results encourage studies to confirm safety and to analyze efficacy. K E Y W O R D S adipose-derived stem cells, cellular therapy, male/female urinary incontinence, phase IIa clinical trial 1 | INTRODUCTION The International Continence Society defines urinary incontinence as "any involuntary loss of urine that is a social or hygienic problem." Following benign prostatic hyperplasia surgery, a mean of 0.5% to 2%

show abstract

Efficiency of Mesenchymal Stem Cells in Treatment of Urinary Incontinence: a Systematic Review on Animal Models

Cited by 4 publications

References 44 publications

Cell Technologies in the Stress Urinary Incontinence Correction

Cell Technologies in the Stress Urinary Incontinence Correction

Development of Male External Urethral Sphincter and Tissue-Resident Stem/Progenitor Cells in Rats

Two phase I/II clinical trials for the treatment of urinary incontinence with autologous mesenchymal stem cells

Contact Info

Product

Resources

About